Buscar
Caribou Biosciences Inc
CRBUAñadir a la lista de seguimiento
1.460USD
-0.050-3.31%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
144.80MCap. mercado
PérdidaP/E TTM
Más Datos de Caribou Biosciences Inc Compañía
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Información de Caribou Biosciences Inc
Símbolo de cotizaciónCRBU
Nombre de la empresaCaribou Biosciences Inc
Fecha de salida a bolsaJul 23, 2021
Director ejecutivoHaurwitz (Rachel E)
Número de empleados147
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 23
Dirección2929 7Th Street, Ste 120
CiudadBERKELEY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94710
Teléfono15109826030
Sitio Webhttps://www.cariboubio.com/
Símbolo de cotizaciónCRBU
Fecha de salida a bolsaJul 23, 2021
Director ejecutivoHaurwitz (Rachel E)
Ejecutivos de Caribou Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
391.94K
-6.98%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
-316.82%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Ms. Ruhi A. Khan
Ms. Ruhi A. Khan
Chief Business Officer
Chief Business Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Natalie R. Sacks, M.D.
Dr. Natalie R. Sacks, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
391.94K
-6.98%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
-316.82%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Caribou Biosciences Inc?
Los cinco principales accionistas de Caribou Biosciences Inc son: Ms. Barbara G. McClung, J.D.
¿Cuántas instituciones poseen acciones de Caribou Biosciences Inc (CRBU)?
A fecha de 2026Q1, 337 instituciones poseen acciones de Caribou Biosciences Inc, con un valor de mercado combinado de aproximadamente 35.96M, lo que representa el 36.25% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -24026667.00.